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Abstract
Background: Red yeast rice (i.e., rice fermented with Monascus spp.), as a food supplement, is claimed to be blood
cholesterol-lowering. The red yeast rice constituent monacolin K, also known as lovastatin, is an inhibitor of the
hydroxymethylglutaryl-CoA (HMG-CoA) reductase. This article aims to develop a sensitive nuclear magnetic
resonance (NMR) method to determine the total statin content of red yeast rice products.
Methods: The total statin content was determined by a 400 MHz
1H NMR spectroscopic method, based on the
integration of the multiplet at δ 5.37-5.32 ppm of a hydrogen at the hexahydronaphthalene moiety in comparison
to an external calibration with lovastatin. The activity of HMG-CoA reductase was measured by a commercial
spectrophotometric assay kit.
Results: The NMR detection limit for total statins was 6 mg/L (equivalent to 0.3 mg/capsule, if two capsules are
dissolved in 50 mL ethanol). The relative standard deviations were consistently lower than 11%. The total statin
concentrations of five red yeast rice supplements were between 1.5 and 25.2 mg per specified daily dose. A dose-
dependent inhibition of the HMG-CoA reductase enzyme activity by the red yeast rice products was demonstrated.
Conclusion: A simple and direct NMR assay was developed to determine the total statin content in red yeast rice.
The assay can be applied for the determination of statin content for the regulatory control of red yeast rice
products.
Background
The fermentation products of Monascus, have been used
as food and traditional Chinese medicine for over 1000
years [1]. The products are called “Hong Qu”, “Hon-
Chi”, “Anka” or “Ang-kak” in China and Taiwan, “Beni
Koji” or “red Koji” in Japan. In Europe, the products are
called “red yeast rice”, “red rice”, “red mould rice” or
“red Chinese rice”. It should be noted that the designa-
tion “yeast” is taxonomically not correct [1]. Red yeast
rice is used as an additive for the colouring, flavouring
and preservation of foods, which may be permitted in
some Asian countries but not in Europe. Currently red
yeast rice products are predominantly marketed as food
supplements, primarily sold through the Internet [2].
Monacolin compounds are formed by Monascus dur-
ing the fermentation process. They cause a reversible
competitive inhibition of the microsomal hydroxy-
methyl-glutaryl coenzyme A (HMG-CoA) reductase;
thus, they prevent the reduction of HMG-CoA to meva-
lonic acid and the formation of cholesterol [2]. The
major Monascus metabolite is monacolin K, which is
structurally identical to lovastatin, the first statin drug
introduced into the market [3,4]. The red yeast rice pro-
ducts that are currently marketed as food supplements
differ from the traditional red yeast rice that is sold in
Chinese groceries. The food supplements are manufac-
tured using selected Monascus strains under carefully
controlled and fully monitored conditions to increase
the monacolin content [5].
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recently provided a scientific opinion on the health
claims related to monacolin K from red yeast rice [6].
The opinion was based on two double-blind, placebo-
controlled human intervention studies, which demon-
strated a significant reduction in total cholesterol con-
centrations in the red yeast rice treatment groups
compared to the placebo groups [7,8]. Besides these
clinical trials, other studies also supported the efficacy
of red yeast rice [9-11], as reviewed by Liu et al. [12]. A
study regarding cholesterol synthesis in human hepatic
cells in vitro showed that the inhibition of HMG-CoA
reductase was facilitated by red yeast rice preparations,
like lovastatin [13]. The monacolin K prepared from red
yeast rice was effective for the maintenance of normal
blood LDL-cholesterol levels [6]. As the EFSA [6] has
not classified such products as food or medicine, the
EFSA’s opinion should not be interpreted as an approval
of red yeast rice for food or medicinal use.
Red yeast rice is expected to have the adverse effects
of its constituent lovastatin, including an increased risk
of myopathy [14-18], acute rhabdomyolysis [19], symp-
tomatic hepatitis [20] and anaphylactic reactions [21].
Drug interactions may influence liver enzyme expression
leading to a lower clearance and elevated plasma con-
centration of lovastatin (e.g., by inhibition of cytochrome
P450 enzyme CYP3A4) [19,22]. When lovastatin is
administered with food, the intestinal absorption may be
increased by about 50%, while pectin and oat bran may
decrease its absorption [22-24]. The excessive use of
grapefruit juice may inhibit CYP3A4 and lead to higher
plasma concentrations of lovastatin [25,26].
Accurate determination of the statin content in red
yeast rice products would be necessary for the regula-
tory control. Previous analytical approaches mainly used
high-performance liquid chromatography (HPLC) with
diode array or mass spectrometric detectors [27-33].
Song et al. [34] suggested a flow injection tandem mass
spectrometry for screening analysis. Chromatographic
and mass spectrometric methods have some problems
in separating over 14 monacolins and avoiding co-elut-
ing interferences that could cause overestimation of the
quantities of the analytes [34]. Furthermore, an equili-
brium exists between monacolin K and its lactone ring
opened hydroxy acid form (ratio between 2:1 and 3:2),
which can be chromatographically separated [32]. For
this reason, the total monacolin content should be
determined for the evaluation of such products
[28,32,35]. The exclusive determination of the lactone
form of monacolin K could underestimate the pharma-
cological activity. Accurate quantification for the
hydroxy acid and other monacolin isomers was difficult
because of the lack of commercial reference standards
[34].
In this study, we overcome these problems by nuclear
magnetic resonance (NMR) spectroscopy, which is
advantageous for quantitative pharmaceutical analysis
due to its high selectivity [36]. Dependent on the
selected chemical shifts for quantification, such as pro-
tons at the hexahydronaphthalene moiety common to
all first generation statins [37], the determination of
total statins appears to be feasible with NMR without
reference standards for each specific compound. A com-
mercial HMG-CoA reductase assay kit was used to con-
firm the effects of the red yeast rice. The samples
purchased over the Internet were evaluated by these
methods.
Materials and methods
Samples and sample preparation
An internet search was conducted in November 2011 to
identify the red yeast rice products that were offered at
German speaking websites to German speaking consu-
mers (for exact methodology, see Löbell-Behrends et al.
[38,39]). None of the identified products was available in
conventional retail stores. We purchased five different
products, all were marketed to German consumers as
food supplements in capsule form (i.e., the red yeast rice
is provided in powder form inside a capsule).
For sample preparation, the content of two capsules
(about 0.9 g) was dissolved in 50 mL of absolute ethanol
(Merck, Darmstadt, Germany). An aliquot of 170 μLo f
this solution was mixed with 370 μL of distilled water
and 60 μLo fp H7 . 4N M Rb u f f e r( 1 . 5MK H 2PO4 in
D2O, 0.1% 3-(trimethylsilyl)-propionate acid-d4 (TSP), 3
mM NaN3). The mixture was poured into an NMR tube
and directly measured. A lovastatin (Teva, Debrecen,
Hungary) stock solution (500 mg/L) was prepared in
absolute ethanol. For calibration, standards were pre-
pared by diluting the lovastatin stock solution with etha-
nol (40% vol).
NMR Method
All
1H NMR measurements were performed using a
Bruker Avance 400 Ultrashield spectrometer (Bruker
BioSpin, Rheinstetten, Germany) equipped with a 5-mm
SEI probe with Z-gradient coils and an Automatic Sam-
ple Changer B-ACS 120 (Bruker BioSpin, Rheinstetten,
Germany). All spectra were acquired at 300.0 K.
The NMR method was modified from our previous
work for testing other products [40]. Two successive
1H
NMR experiments were used for the measurement of
each sample. First, the standard Bruker BioSpin water
pre-saturation pulse program ZGPR was used to sup-
press only the signal of OH-protons. The relaxation
delay (RD), and acquisition time (AQ) were set to 4 s
and 3.99 s, respectively, resulting in a total recycle time
of 7.99 s. After application of four dummy scans (DS),
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= 8) were collected into a time domain (TD) of 65536
(65 k) complex data points using a 20.5187 ppm spectral
width and a receiver gain of 1. The FIDs were multiplied
with an exponential function corresponding to a line
broadening of 1 Hz prior to Fourier transformation. Sec-
ond, 8-fold suppression of water and ethanol was per-
formed with the frequencies identified in the first
experiment (Bruker sequence NOESYGPPS1D). The set-
tings for the parameters RD, P(90°), AQ, and TD were
kept similar to the ones from the first experiment, DS =
4 and NS = 32 were used and the mixing time (tm)w a s
set to 10 ms.
The data were acquired automatically under the con-
trol of ICON-NMR (Bruker BioSpin, Rheinstetten, Ger-
many), requiring about 12 min per sample. All NMR
spectra were phased, baseline-corrected and integrated
using Topspin 3.1 (Bruker BioSpin, Rheinstetten, Ger-
many). For quantification, linear calibration curves were
constructed from the lovastatin standards by integrating
the multiplet at δ 5.37-5.32 ppm against TSP as an
intensity reference. All measurements were done in five
replicates including sample preparation. For
1HN M R
spectral prediction, the software ChemBioDraw 12.0
(CambridgeSoft, Cambridge, UK) was used. The spectral
prediction was performed according to Schaller et al.
[41].
Validation of NMR method
For method validation, standard solutions and authentic
red yeast rice samples were analyzed several times on
one day (intraday, n = 5) and over five consecutive days
(interday, n = 10). The linearity of the calibration curves
was evaluated in the range covering the concentrations
found in the investigated products. The recovery rate
was ascertained by adding lovastatin standard solution
at two different concentrations to a real sample. The
limits of detection (LOD) and quantification (LOQ)
were calculated from the residual standard deviation of
the regression line [42].
HMG-CoA reductase assay
The HMG-CoA reductase (HMGR) assay kit #CS1090
from Sigma-Aldrich (Saint Louis, MO, USA) was used.
The procedure was modified from Perchellet et al. [43],
and according to the manufacturer’s instructions, with
the exception of an additional dilution 1:3 in assay buf-
fer to facilitate the use of standard 1 cm cuvettes (i.e., 3
mL final volume instead of 1 mL volume). The inhibitor
solution (pravastatin) provided with the kit was used as
positive control.
The red yeast rice sample solutions prepared for NMR
analysis were used for the assay in appropriate dilution.
Spectrophotometric measurements were performed on a
Perkin Elmer Lambda 20 dual beam spectrometer (Per-
kin Elmer, Rodgau, Germany) at 37°C. The spectrometer
was operated with the Perkin Elmer UV WinLab soft-
ware (version 2.85.04) in time drive mode. The absor-
b a n c ea t3 4 0n mw a sm o n i t o r e da tat i m ei n t e r v a lo f
1.00 s for a total time of 15 min. The slit width was
1.00 nm and the response time 0.1 s.
Statistical methods
All data were evaluated using Origin V.7.5 (OriginLab,
Northampton, USA). Data are presented as means and
standard deviations among replicates. Linear regression
analysis was used to compare NMR responses and con-
centrations. P < 0.05 was considered statistically
significant.
Results and discussion
NMR quantification results
NMR determination of lovastatin showed resonances at
δ 6.05-6.01 ppm, δ 5.90-5.84 ppm, δ 5.61-5.56 ppm, δ
5.37-5.32 ppm, δ 4.39-4.34 ppm (mid-field region) and δ
2.85-2.76 ppm, δ 2.63-2.56 ppm, δ 2.44-2.33 ppm, δ
1.98-1.93 ppm, δ 1.64-1.57 ppm, δ 0.91-0.85 ppm (ali-
phatic range) through comparing the spectra of lovasta-
tin standard solutions with the spectra of authentic red
yeast rice samples (Figure 1). However, the resonances
in the aliphatic range were unsuitable for quantification
because they showed strong overlap with matrix com-
pounds (Figure 1A, B). Considering signals in the mid-
field region (Figure 1C, D), we used the multiplet at δ
5.37-5.32 ppm for quantification because this led to the
best sensitivity and this signal was not interfered in any
case in our samples. Thus, more advanced techniques,
such as multivariate regression or curve deconvolution,
were not required.
A spectral assignment of lovastatin was provided by
Chen et al. [44] at 600 MHz in D-methanol, by Holz-
grabe et al. [ 4 5 , 4 6 ]a t3 0 0M H zi nC D C l 3,b yA h m a det
al. [47] at 300 MHz in DMSO-d6, and by Lankhorst et
al. [48] at 600 MHz in CDCl3. While our conditions are
not directly comparable to any of these studies, the lit-
erature data along with own spectral prediction show
that the multiplet at δ 5.37-5.32 ppm clearly belongs to
an H-atom at the hexahydronaphthalene moiety (Figure
2), most probably H6, H4 or an overlap of the signals of
both atoms. A final spectral assignment would necessi-
tate further 2D experiments outside the scope of this
work. The use of a chemical shift belonging to the hexa-
hydronaphthalene moiety has the advantage that not
only the sum of the lactone and hydroxy acid forms of
monacolin K (lovastatin) can be quantified, but a sum of
all statins that contain the hexahydronaphthalene moi-
ety, including monacolins J, L, M, or X in red yeast rice
[1,29,49] and other first generation statins (e.g., used as
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tion synthetic statins [37]. We therefore referred the
results of our method to “total statins”, not lovastatin or
monacolin content.
Table 1 summarizes the NMR method validation
results for lovastatin. The
1H NMR assay was linear in
a working concentration range of 5-100 mg/L (R =
0.98, P < 0.0001). The LOD and LOQ were 6 and 13
mg/L, respectively, which were equal to 0.33 and 0.72
mg/capsule if two capsules were dissolved in 50 mL
ethanol. These results were suitable for estimating the
levels of lovastatin in red yeast rice products. The
method was further validated by repeated sample pre-
parations of standard samples and authentic red yeast
rice samples. For the standard solutions, all relative
standard deviations (RSD) were below 8% (intraday)
and 9% (interday). For the authentic samples, the RSDs
were slightly higher but still below 11%. The method
validation result shows that the method is sufficiently
precise and reproducible and can be used for analysis
of authentic samples (Table 1).
Five authentic red yeast rice products were analyzed
by the validated method. Figure 3 shows the NMR
peaks of integration from all analyzed products (S1-S5)
in comparison with two reference spectra of lovastatin
(10 and 100 mg/L). According to the
1HN M Rd a t a ,a l l
five analyzed samples contained statins ranging from 1.5
mg/capsule (S1) to 8.0 mg/capsule (S5) (Table 2). The
Figure 1 400 MHz
1H NMR spectra of lovastatin standard (50 mg/L, solid line) compared with a red yeast rice product (sample S4,
dashed line).
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Figure 2 Lovastatin (monacolin K) may occur in red yeast rice
as lactone (A) or hydroxy acid (B).
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ling for two of the products (S1 and S5; for the other
three products no labelling was provided). The deter-
mined concentrations correspond to a range between
1.5 and 25.2 mg per specified daily dose. Three of five
investigated products (S3-5) had a dose higher than the
starting dosage of prescription (10 mg per day) in
humans [50-52]. Our results confirmed the previous stu-
dies that there is a wide variability in total statin content
among different red yeast rice products [28,35] as well
as a lack in product standardization [33]. Four out of
t h ef i v er e dy e a s tr i c ep r o d u c t sa n a l y z e di nt h i ss t u d y
failed to comply with the current European Union food
labelling and food supplements regulations.
HMG-CoA reductase inhibition
Besides monacolin K, red yeast rice may contain several
different monacolins with statin-like activity. Figure 4
shows that the activities were almost congruent (e.g.,
compare lovastatin at 50 μMa n dS 1a t5 0μM) when
the total statin content in a red yeast rice sample was
adjusted to the same molarity as a lovastatin standard.
The inhibitory effect on HMG-CoA reductase was
visually clear in Figure 4 to be related to the doses. In
other words, the higher was the concentration of total
statins in the red yeast rice, the greater the inhibitory
effect exhibited. These results suggest that NMR can be
used to determine the content of statins that would
have inhibitory effect on HMG-CoA reductase.
Conclusion
A simple and direct NMR assay was developed to deter-
mine the total statin content in red yeast rice. The assay
can be applied for the determination of statin content
for the regulatory control of red yeast rice products.
Table 1 Results of method validation for monacolin K
(lovastatin) using
1H NMR
Parameter Result
Investigated linear working range 5 - 100 mg/L
Limit of detection
a 6 mg/L (0.33 mg/capsule
c)
Limit of quantitation
a 13 mg/L (0.72 mg/capsule
c)
Intraday precision
b
Authentic sample
d 10%
Standard solution 7.3%
Interday precision
b
Authentic sample
d 11%
Standard solution 8.2%
Recovery 104% (at 50 mg/L)
113% (at 20 mg/L)
a Limit of detection (LOD) and quantitation were determined by establishing a
separate calibration curve near LOD. The limits were calculated from the
residual standard deviation of the regression line [42]
b Precisions were expressed as relative standard deviation (%), intraday (n =
5), interday (n = 10)
c Based on a sample weight of 0.9 g (2 capsules) in 50 mL ethanol
d Total statins in authentic samples
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Figure 3 400 MHz
1H NMR spectra of pure lovastatin and red
yeast rice samples (S1-S5).
Table 2 Results of the quantitative
1H NMR determination of total statins in red yeast rice products
Sample Sample Labelling Product origin Total statins (NMR) Labelling of
monacolin K
(mg/capsule)
(mg/
capsule)
a
(mg/daily
dose)
b
S1 Red rice, food supplement, 330 mg capsules (in German) Austria 1.5 ± 0.1 1.5 - 4.5 1.33
S2 Red yeast rice, food supplement, 600 mg capsules (in English) USA with UK
labelling
3.3 ± 0.4 6.6 no labelling
S3 Red yeast rice, herbal supplement, 330 mg capsules (in English) UK 5.3 ± 0.6 10.6 no labelling
S4 Red yeast rice, dietary supplement, 600 mg capsules (in English) USA 6.3 ± 0.2 12.6 - 25.2 no labelling
S5 Red yeast rice, food supplement, 600 mg capsules (in French) France 8.0 ± 0.6 16.0 - 24.0 9.6
a Means ± standard deviations (SD) based on 5 replicated measurements (including sample preparation)
b The daily doses were calculated according to our analytical result and the intake recommendation of the products (a range is given when the manufacturer
recommended a range for daily dose)
Lachenmeier et al. Chinese Medicine 2012, 7:8
http://www.cmjournal.org/content/7/1/8
Page 5 of 7Acknowledgements
The authors warmly thank Hannelore Heger for excellent technical
assistance. The study was funded by a grant from the Ministry of Rural
Affairs and Consumer Protection of the German federal state of Baden-
Württemberg (Stuttgart, Germany). The funder played no role in study
design, collection, data analysis and interpretation, report writing and
decision to submit the paper for publication. This paper does not necessarily
represent the views of the Ministry of Rural Affairs and Consumer Protection.
Author details
1Chemisches und Veterinäruntersuchungsamt (CVUA) Karlsruhe,
Weissenburger Strasse 3, 76187 Karlsruhe, Germany.
2Bruker Biospin GmbH,
Silbersteifen, 76287 Rheinstetten, Germany.
3Department of Chemistry,
Saratov State University, Astrakhanskaya Street 83, 410012 Saratov, Russia.
4Stabsstelle Ernährungssicherheit, Regierungspräsidium Tübingen, Konrad-
Adenauer-Strasse 20, 72072 Tübingen, Germany.
5Andreas-Schlüter-Strasse
19, 53639 Königswinter, Germany.
Authors’ contributions
DWL conceived of the study, coordinated the work, and wrote the
manuscript. YBM carried out the NMR experiments including data acquisition
and analysis, prepared the tables and figures, and wrote the materials and
methods section of the manuscript. TK supervised the NMR work and
revised the manuscript. SLB conducted the Internet search, purchased the
products and revised the manuscript. SM conducted the checking of the
food labelling of the products. SM, MKH and AW contributed knowledge
about the regulatory control of the products and revised the manuscript. CS
conceived of the study on the red yeast rice products sold on the Internet
and the use of the HMG-CoA reductase assay, contributed to writing the
introduction and discussion sections, and revised the manuscript. All authors
read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 18 January 2012 Accepted: 22 March 2012
Published: 22 March 2012
References
1. Wang TH, Lin TF: Monascus rice products. Adv Food Nutr Res 2007,
53:123-159.
2. DFG - Senate Commission on Food Safety: Toxicological evaluation of red
mould rice Bonn, Germany: Deutsche Forschungsgemeinschaft (DFG)
[German Research Foundation]; 2005.
3. Henwood JM, Heel RC: Lovastatin. A preliminary review of its
pharmacodynamic properties and therapeutic use in hyperlipidaemia.
Drugs 1988, 36:429-454.
4. Tobert JA: Lovastatin and beyond: the history of the HMG-CoA reductase
inhibitors. Nat Rev Drug Discov 2003, 2:517-526.
5. Havel RJ: Dietary supplement or drug? The case of cholestin. Am J Clin
Nutr 1999, 69:175-176.
6. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA): Scientific
Opinion on the substantiation of health claims related to monacolin K
from red yeast rice and maintenance of normal blood LDL-cholesterol
concentrations (ID 1648, 1700) pursuant to Article 13(1) of Regulation
(EC) No 1924/2006. EFSA J 2011, 9:2304.
7. Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, Go VL: Cholesterol-
lowering effects of a proprietary Chinese red-yeast-rice dietary
supplement. Am J Clin Nutr 1999, 69:231-236.
8. Lin CC, Li TC, Lai MM: Efficacy and safety of Monascus purpureus Went
rice in subjects with hyperlipidemia. Eur J Endocrinol 2005, 153:679-686.
9. Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ: Red yeast
rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann
Intern Med 2009, 150:830-839.
10. Halbert SC, French B, Gordon RY, Farrar JT, Schmitz K, Morris PB,
Thompson PD, Rader DJ, Becker DJ: Tolerability of red yeast rice (2,400
mg twice daily) versus pravastatin (20 mg twice daily) in patients with
previous statin intolerance. Am J Cardiol 2010, 105:198-204.
11. Bogsrud MP, Ose L, Langslet G, Ottestad I, Strøm EC, Hagve TA, Retterstøl K:
HypoCol (red yeast rice) lowers plasma cholesterol - a randomized
placebo controlled study. Scand Cardiovasc J 2010, 44:197-200.
12. Liu J, Zhang J, Shi Y, Grimsgaard S, Alraek T, Fønnebø V: Chinese red yeast
rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of
randomized controlled trials. Chin Med 2006, 1:4.
13. Man RY, Lynn EG, Cheung F, Tsang PS, O K: Cholestin inhibits cholesterol
synthesis and secretion in hepatic cells (HepG2). Mol Cell Biochem 2002,
233:153-158.
14. Polsani VR, Jones PH, Ballantyne CM, Nambi V: A case report of myopathy
from consumption of red yeast rice. J Clin Lipidol 2008, 2:60-62.
15. Lapi F, Gallo E, Bernasconi S, Vietri M, Menniti-Ippolito F, Raschetti R, Gori L,
Firenzuoli F, Mugelli A, Vannacci A: Myopathies associated with red yeast
rice and liquorice: spontaneous reports from the Italian Surveillance
System of Natural Health Products. Br J Clin Pharmacol 2008, 66:572-574.
16. Smith DJ, Olive KE: Chinese red rice-induced myopathy. South Med J 2003,
96:1265-1267.
17. Prasad GV, Wong T, Meliton G, Bhaloo S: Rhabdomyolysis due to red yeast
rice (Monascus purpureus) in a renal transplant recipient. Transplantation
2002, 74:1200-1201.
18. Mueller PS: Symptomatic myopathy due to red yeast rice. Ann Intern Med
2006, 145:474-475.
19. Mastaglia FL, Needham M: Update on toxic myopathies. Curr Neurol
Neurosci Rep 2012, 12(1):54-61, DOI: 10.1007/s11910-011-0232-9.
20. Roselle H, Ekatan A, Tzeng J, Sapienza M, Kocher J: Symptomatic hepatitis
associated with the use of herbal red yeast rice. Ann Intern Med 2008,
149:516-517.
21. Hipler UC, Wigger-Alberti W, Bauer A, Elsner P: Monascus purpureus-a new
fungus of allergologic relevance. Mycoses 2002, 45:58-60.
22. Lennernäs H, Fager G: Pharmacodynamics and pharmacokinetics of the
HMG-CoA reductase inhibitors. Similarities and differences. Clin
Pharmacokinet 1997, 32:403-425.
23. Vaquero MP, Sánchez Muniz FJ, Jiménez Redondo S, Prats Oliván P,
Higueras FJ, Bastida S: Major diet-drug interactions affecting the kinetic
characteristics and hypolipidaemic properties of statins. Nutr Hosp 2010,
25:193-206.
24. Garnett WR: Interactions with hydroxymethylglutaryl-coenzyme A
reductase inhibitors. Am J Health Syst Pharm 1995, 52:1639-1645.
25. Messer A, Raquet N, Lohr C, Schrenk D: Major furocoumarins in grapefruit
juice II: Phototoxicity, photogenotoxicity, and inhibitory potency vs.
Figure 4 In vitro inhibition of human HMG-CoA reductase at
increasing concentrations of monacolins in commercial red
yeast rice product and pure lovastatin. Results are expressed as
% of the respective control specific activity of the enzyme in the
absence of inhibitor (mean of two replicates; error bar: standard
deviation).
Lachenmeier et al. Chinese Medicine 2012, 7:8
http://www.cmjournal.org/content/7/1/8
Page 6 of 7cytochrome P450 3A4 activity. Food Chem Toxicol 2012, 50(3-4):756-760,
DOI: 10.1016/j.fct.2011.11.023.
26. Bailey DG, Malcolm J, Arnold O, Spence JD: Grapefruit juice-drug
interactions. Br J Clin Pharmacol 1998, 46:101-110.
27. Huang HN, Hua YY, Bao GR, Xie LH: The quantification of monacolin K in
some red yeast rice from Fujian province and the comparison of the
other product. Chem Pharm Bull (Tokyo) 2006, 54:687-689.
28. Gordon RY, Cooperman T, Obermeyer W, Becker DJ: Marked variability of
monacolin levels in commercial red yeast rice products: buyer beware.
Arch Intern Med 2010, 170:1722-1727.
29. Li YG, Zhang F, Wang ZT, Hu ZB: Identification and chemical profiling of
monacolins in red yeast rice using high-performance liquid
chromatography with photodiode array detector and mass
spectrometry. J Pharm Biomed Anal 2004, 35:1101-1112.
30. Chairote E, Chairote G, Niamsup H, Lumyong S: The presence and the
content of Monacolins in Red Yeast rice prepared from Thai glutinous
rice. World J Microbiol Biotechnol 2008, 24:3039-3047.
31. Chairote E, Lumyong S, Chairote G: Study on cholesterol lowering
compounds in red yeast rice prepared from Thai glutinous rice. As J
Food Ag-Ind 2010, 3:217-228.
32. Ma J, Li Y, Ye Q, Li J, Hua Y, Ju D, Zhang D, Cooper R, Chang M:
Constituents of red yeast rice, a traditional Chinese food and medicine.
J Agric Food Chem 2000, 48:5220-5225.
33. Heber D, Lembertas A, Lu QY, Bowerman S, Go VL: An analysis of nine
proprietary Chinese red yeast rice dietary supplements: implications of
variability in chemical profile and contents. J Altern Complement Med
2001, 7:133-139.
34. Song F, El-Demerdash A, Lee SJ, Smith RE: Fast screening of lovastatin in
red yeast rice products by flow injection tandem mass spectrometry.
J Pharm Biomed Anal 2012, 57:76-81.
35. Steffen C: Abgrenzungsproblematik. Klinische Studien mit
Nahrungsergänzungsmitteln. Pharm Unserer Zeit 2011, 40:332-337.
36. Holzgrabe U, Wawer I, Diehl B: NMR spectroscopy in pharmaceutical analysis
Amsterdam, The Netherlands: Elsevier Science; 2008.
37. Kerpel-Fronius S, Fischer J: Optimizing the clinical pharmacologic
properties of the HMG-CoA reductase inhibitors. In Analogue-based Drug
Discovery. Edited by: Fischer J, Ganellin CR. Weinheim, Germany: Wiley-VCH;
2006:137-156.
38. Löbell-Behrends S, Maixner S, Kratz E, Kohl-Himmelseher M, Bauer-
Aymanns H, Marx G, Lachenmeier DW: Surveillance of internet marketing
of borderline products (anti-aging and weight-loss supplements): A pilot
study. Deut Lebensm Rundsch 2008, 104:265-270.
39. Löbell-Behrends S, Böse W, Maixner S, Kratz E, Kohl-Himmelseher M, Marx G,
Lachenmeier DW: Surveillance of internet marketing of food products -
categorization of borderline products and concepts for effective control
strategies. J Verbr Lebensm 2011, 6:385-393.
40. Monakhova YB, Schäfer H, Humpfer E, Spraul M, Kuballa T,
Lachenmeier DW: Application of automated eightfold suppression of
water and ethanol signals in
1H NMR to provide sensitivity for analyzing
alcoholic beverages. Magn Reson Chem 2011, 49:734-739.
41. Schaller RB, Munk ME, Pretsch E: Spectra estimation for computer-aided
structure determination. J Chem Inf Comput Sci 1996, 36:239-243.
42. DIN 32 645: Chemische Analytik: Nachweis-, Erfassungs- und
Bestimmungsgrenze, Ermittlung unter Wiederholbedingungen. Begriffe,
Verfahren, Auswertung Berlin, Germany: Beuth Verlag; 1994.
43. Perchellet JP, Perchellet EM, Crow KR, Buszek KR, Brown N, Ellappan S,
Gao G, Luo D, Minatoya M, Lushington GH: Novel synthetic inhibitors of
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity
that inhibit tumor cell proliferation and are structurally unrelated to
existing statins. Int J Mol Med 2009, 24:633-643.
44. Chen LC, Lai YK, Wu SC, Lin CC, Guo JH: Production by Clonostachys
compactiuscula of a lovastatin esterase that converts lovastatin to
monacolin J. Enzyme Microb Technol 2006, 39:1051-1059.
45. Diehl BWK, Holzgrabe U: Analysis of Drugs. In NMR Spectroscopy in Drug
Development and Analysis. Edited by: Holzgrabe U, Wawer I, Diehl B.
Weinheim, Germany: Wiley-VCH; 1999:16-60.
46. Holzgrabe U, Diehl BW, Wawer I: NMR spectroscopy in pharmacy. J Pharm
Biomed Anal 1998, 17:557-616.
47. Ahmad A, Panda BP, Khan S, Ali M, Javed S: Downstreaming and
purification of lovastatin from Monascus purpureus culture. Thai J Pharm
Sci 2009, 33:39-46.
48. Lankhorst PP, Poot MM, de Lange MPA: Quantitative Determination of
Lovastatin and Dihydrolovastatin by Means of
1H NMR Spectroscopy.
Pharmacopeial Forum 1996, 22:2414-2422.
49. Juzlová P, Martinková L, Kren V: Secondary metabolites of the fungus
Monascus: a review. J Ind Microbiol Biotechnol 1996, 16:163-170.
50. Walker JF, Tobert JA: The clinical efficacy and safety of lovastatin and
MK-733-an overview. Eur Heart J 1987, 8(Suppl. E):93-96.
51. Lamson M, Phillips G, Shen J, Lukacsko P, Friedhoff L, Niecestro RM:
Pharmacokinetics of lovastatin extended-release dosage form
(Lovastatin XL) in healthy volunteers. Biopharm Drug Dispos 2002,
23:143-149.
52. Shear CL, Franklin FA, Stinnett S, Hurley DP, Bradford RH, Chremos AN,
Nash DT, Langendorfer A: Expanded Clinical Evaluation of Lovastatin
(EXCEL) study results. Effect of patient characteristics on lovastatin-
induced changes in plasma concentrations of lipids and lipoproteins.
Circulation 1992, 85:1293-1303.
doi:10.1186/1749-8546-7-8
Cite this article as: Lachenmeier et al.: NMR evaluation of total statin
content and HMG-CoA reductase inhibition in red yeast rice (Monascus
spp.) food supplements. Chinese Medicine 2012 7:8.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Lachenmeier et al. Chinese Medicine 2012, 7:8
http://www.cmjournal.org/content/7/1/8
Page 7 of 7